Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.52 |
| ▸ | CTSS | P25774 | 13/20 | 0.52 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSB | P07858 | 8/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24961119 | 0.83 | CTSL (0.62) | CTSLCTSSCTSKCTSB | |
| SCHEMBL26534569 | 0.78 | CTSL (0.51) | CTSLCTSSCTSKCTSBTACR1 | |
| SCHEMBL26534342 | 0.78 | DRD2 (0.50) | CTSLCTSS | |
| SCHEMBL24961003 | 0.78 | CTSK (0.54) | CTSLCTSSCTSKCTSB | |
| SCHEMBL24961235 | 0.77 | CTSS (0.53) | CTSLCTSSCTSKCTSB | |
| SCHEMBL29332815 | 0.75 | CTSK (0.54) | CTSLCTSSCTSKCTSB | |
| SCHEMBL24961118 | 0.73 | CTSL (0.67) | CTSLCTSSCTSKCTSB | |
| SCHEMBL24961122 | 0.73 | CTSL (0.68) | CTSLCTSSCTSKCTSB | |
| SCHEMBL26223994 | 0.73 | CTSL (0.61) | CTSLCTSSCTSKCTSB | |
| SCHEMBL24960954 | 0.73 | CTSL (0.64) | CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSS 45/4885CTSK 86/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSS 45/4885CTSK 86/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSS 45/4885CTSK 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.